AI meets AR: How Rokid Glasses bring multilingual, real-time intelligence to smart eyewear globally
Updated
March 17, 2026 1:01 AM
Rokid's smart glasses. PHOTO: ROKID
Rokid, a Chinese company specializing in AI-powered smart eyewear and human–computer interaction, has rolled out a major software update for the international version of its Rokid Glasses. This update makes it the first smart glasses manufacturer to natively support Google’s Gemini, alongside three other leading large language models: OpenAI’s ChatGPT, Alibaba’s Qwen and DeepSeek.
The integration is powered by Rokid’s device-to-cloud architecture, which enables users to switch between AI models on the fly. In practice, this means a traveler can receive a real-time translation in Japanese using one AI model, then quickly switch to ChatGPT to answer a technical query—without noticeable delay. The system also supports multi-modal inputs like voice and gestures, making interactions more intuitive for everyday use.
This is more than a routine software update. By combining AI models from both U.S. and Chinese developers, Rokid is making its smart glasses relevant to global users, with features that adapt to local languages and preferences while maintaining high performance.
These technological advancements have directly fueled Rokid’s international growth. Between November 2024 and October 2025, Shangpu Group data shows Rokid Glasses ranked No.1 in global sales for AI glasses with display functionality. Crowdfunding milestones further reflect this momentum: the product became the fastest smart glasses to raise over 100 million Japanese Yen on Japan’s MAKUAKE platform and broke Kickstarter records for smart eyewear.
Taken together, Rokid’s update highlights a shift in the smart glasses space: success increasingly comes from openness, flexibility and localized AI experiences rather than closed, single-platform ecosystems. By giving users choice, integrating global AI capabilities and bridging cultural and linguistic gaps, Rokid is positioning itself as a serious contender in the international AR and AI wearable market.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.